Decision to list continence products supplied by Downs Distributors Limited
We are pleased to announce the approval of a non-exclusive listing agreement with Downs Distributors Limited for the supply of continence products to DHBs.
What we’re doing
We are pleased to announce the approval of a non-exclusive listing agreement with Downs Distributors Limited (“Downs”) for the supply of continence products to DHBs.
In summary, this will result in:
- Downs’ continence products being listed in Part III of Section H of the Pharmaceutical Schedule from 1 September 2019; and
- DHBs being able to continue to purchase other suppliers’ brands of continence products as the agreement is not for sole supply.
Any changes to the original proposals?
No changes were made to the original proposal as a result of consultation feedback.
Who we think will be most interested
- Suppliers and Wholesalers
- DHB Staff
- clinical staff in a range of inpatient, outpatient and community settings where continence products are used
- procurement and supply chain personnel
Detail about this decision
The RFP requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.
After evaluating Downs’ proposal, and consulting on the provisional agreement reached, PHARMAC has decided to list continence products supplied by Downs’ in Part III of Section H of the Pharmaceutical Schedule from 1 September 2019.
The brands included in the agreement are:
- Needs Ltd
This agreement is the latest to arise from the urology, ostomy and continence RFP.
DHBs can continue to choose which continence products they purchase, including those from other suppliers. DHBs that purchase Downs’ products listed on the Pharmaceutical Schedule, must do so under the terms and conditions, and at the prices, included in the agreement, from 1 September 2019.
PHARMAC expects to reach agreements with a number of other suppliers over the coming months for the supply of urology, ostomy and continence products to DHBs.
Our response to what you told us
We appreciate the time people took to consider this consultation.
One consultation response was received by 16 April 2019, from the Ministry of Health, advising that no technical or resource impacts were expected as a result of the proposal. This feedback was considered prior to making the decision to approve the agreement.
If you have any questions about this decision, you can email us at email@example.com; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.